Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial
September 07 2016 - 8:30AM
Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting
and treating cancer, today announced the appointment of Bryce V.
Tenbarge as Vice President of Commercial, effective August 22,
2016. In this newly created role, Mr. Tenbarge will report to Mark
Baker, Chief Executive Officer of Progenics, and will be
responsible for leading all of the Company’s commercial activities.
Mr. Tenbarge brings over fifteen years of experience in
biopharmaceutical marketing, most recently as Vice President of
Marketing and Commercialization at Celldex Therapeutics.
“Bryce is a tenured biopharmaceutical marketing
executive with particular expertise in oncology,” said Mark Baker,
Chief Executive Officer of Progenics. “His proven ability to design
and implement commercial infrastructure, support highly-specialized
product launches, and work in close collaboration with sales
organizations will prove invaluable as we prepare for the potential
commercial launch of our ultra-orphan radiopharmaceutical
candidate, AZEDRA®, and further advance our late-stage prostate
cancer imaging and therapeutics pipeline.”
“Progenics is emerging as a leader in the
development of novel oncology imaging agents and therapeutics, and
I am pleased to be joining the team at this important time,” said
Mr. Tenbarge. “AZEDRA represents a potential breakthrough in the
treatment of malignant pheochromocytomas and paragangliomas, rare
neuroendocrine cancers for which there are currently no approved
therapies, and the Company’s promising pipeline has the potential
to transform how prostate cancer is diagnosed, monitored and
treated. I look forward to working with the Progenics leadership
team to bring these innovative therapies to patients in need.”
Mr. Tenbarge joins Progenics from Celldex
Therapeutics, where he served as Vice President of Marketing and
Commercialization since 2013. From 2012 to 2013, he was Senior
Director of Oncology Marketing at Teva Pharmaceuticals. Prior to
Teva, he held several marketing positions of increasing
responsibility at Bristol-Myers Squibb including Sales, Business
Intelligence, Payer and Professional Marketing. Mr. Tenbarge
received his MBA from The Ross School of Business at the University
of Michigan.
About Progenics
Progenics Pharmaceuticals, Inc. is developing
innovative medicines and other products for targeting and treating
cancer, with a pipeline that includes several product candidates in
later-stage clinical development. These products in development
include therapeutic agents designed to precisely target cancer
(AZEDRA® and 1095), and PSMA-targeted imaging agents for prostate
cancer (1404 and PyL™) intended to enable clinicians and patients
to accurately visualize and manage their disease. Progenics
recently entered into an agreement with a subsidiary of Bayer AG
granting Bayer exclusive worldwide rights to develop and
commercialize products using our PSMA antibody technology in
combination with alpha-emitting radionuclides. In addition,
in late 2015 Progenics acquired EXINI Diagnostics AB, a leader in
the development of advanced artificial intelligence-based imaging
analysis tools and solutions for medical decision support. The
acquisition of EXINI complements Progenics' strategy to support its
imaging and therapeutic agents with sophisticated analytical tools
and other technologies to help physicians and patients visualize,
understand, target and treat cancer. Progenics' first
commercial product, RELISTOR® (methylnaltrexone bromide) for
opioid-induced constipation, is partnered with and marketed by
Valeant Pharmaceuticals International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations, such as the Phase 3
clinical program for 1404; our ability to successfully integrate
EXINI Diagnostics AB and to develop and commercialize its products;
the unpredictability of the duration and results of regulatory
review of New Drug Applications and Investigational NDAs; market
acceptance for approved products; the effectiveness of the efforts
of our partners to market and sell products on which we collaborate
and the royalty revenue generated thereby; generic and other
competition; the possible impairment of, inability to obtain and
costs of obtaining intellectual property rights; possible product
safety or efficacy concerns, general business, financial and
accounting matters, litigation and other risks. More information
concerning Progenics and such risks and uncertainties is available
on its website, and in its press releases and reports it files with
the U.S. Securities and Exchange Commission. Progenics is providing
the information in this press release as of its date and, except as
expressly required by law, Progenics disclaims any intent or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Please follow us on
LinkedIn®. Information on or accessed through our website or social
media sites is not included in the company's SEC filings.
(PGNX-F)
Contact:
Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024